Continuous Renal Replacement Therapy Market to reach USD 2.0 billion in 2030, at a CAGR of 7.8%.

The Continuous Renal Replacement Therapy Market was estimated at USD 1.5 billion in 2023-e and projected to grow at a CAGR of 7.8% through 2030 to reach USD 2.0 billion. The growing pace of technological progress and the introduction of innovative products have significantly increased the adoption of CRRT in the management of critically ill patients. Market players are actively addressing the evolving demand for CRRT products by developing solutions tailored to specific patient populations, including pediatric patients.

For instance, in December 2020, Medtronic launched the Carpediem cardio-renal paediatric dialysis emergency machine, designed for pediatric and neonatal patients weighing between 2.5-10 kilograms, catering to cases involving fluid overload or AKI. Advancements in membrane technology, personalized CRRT delivery, and the integration of data analytics in therapy administration and prescription automation contribute to improving patient care quality, ultimately expanding the market size.

The systems segment led the major share during the forecast period 2024-2030. CRRT systems enable healthcare professionals to oversee critical parameters closely. Their design is portable or stationary, offering flexibility in patient care settings.

The CVVHDF segment accounted for the major share of the continuous renal replacement therapy market in 2023. CVVHDF integrates both hemofiltration and hemodialysis, providing a holistic approach to renal replacement therapy and effectively removing waste products and excess fluids. It also allows for precise control of fluid balance, making it particularly suitable for patients with fluid overload or those requiring strict fluid management.

The adult segment is anticipated to witness significant growth during the forecast period 2023-2030. CRRT is widely employed in adult populations, particularly in ICUs, where critically ill patients experience AKI or other renal complications. Its continuous and gradual nature makes it well-suited for managing hemodynamically unstable adult patients with severe renal dysfunction. Adult patients with conditions such as sepsis, multiple organ failure, or cardiac surgery complications benefit from CRRT as part of their comprehensive care.

Europe is anticipated to witness significant growth in the CRRT market, driven by factors such as growing regulatory approvals in the European Union and a rising number of cases necessitating renal replacement therapy. A noteworthy example is a study published by Kidney Research UK in June 2023, forecasting an anticipated increase in AKI incidence in the UK from an estimated 615,000 episodes in 2022 to 637,000 by 2033. This growth underscores the evolving landscape of the European market and its pivotal role in the CRRT market.

Competitive Landscape

The CRRT market is characterized by the presence of various small and big players. The major market player includes Asahi Kasei Medical, B. Braun, Baxter, Cytosorbents, Fresenius Medical Care, Infomed SA, Medtronic, Nikkiso, NIPRO, and Toray Medical amongst others.  In a competitive market landscape, players are swiftly embracing advanced technologies to enhance CRRT operations and bolster their competitive stance through strategic initiatives, including mergers, acquisitions, and the introduction of new products.

For instance, in April 2022, Baxter International announced the US Food and Drug Administration 510(k) clearance for its ST Set designed for CRRT. Notably, it is actively utilized in Europe, Asia-Pacific, and North and South America, attesting to its global impact and widespread adoption across diverse healthcare settings.